End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
283,500 KRW | -1.05% | -4.87% | -19.57% |
May. 16 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.57% | 2.64B | B | ||
+15.91% | 42.02B | B- | ||
+22.40% | 21.66B | B+ | ||
+18.48% | 15.09B | - | ||
+16.12% | 14.21B | B+ | ||
+45.12% | 12.37B | B | ||
-0.05% | 6.79B | - | - | |
-9.58% | 6.59B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.18% | 5.56B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A128940 Stock
- Ratings Hanmi Pharm. Co., Ltd.